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Results: Assessment of remodelling deformation in the LAD distribution (n=Z) revealed 
an increase in wall thickness (E33=0.14. 0.16) and the range of transverse shears (E13. 
E23) from 4.02 to ~0.1. resulting in net increase in tissue volume (product of stretch 
ratios: 1.21, 1.04). lmmunohistochemistry revealed evidence of UPA transfection in the 
LAD distribution (n=i), and an increase in type I collagen degradation in the LAD distrfbu- 
tion, compared with the LCx distribution (n=2). No increase in type I collagen degradation 
was observed in both the LAD and LCx distribution of the pig in which )?-galactosidase 
gene was delivered (n=l). 
Conclusion: Results from this ongoing study indicate that UPA induces extracellular 
matrix degradation, yielding altered ventricular remodelling. 
4:30 p.m. 
864-3 Reduction of Secondary Vasospasm Limits 
Cardiomyopathy Progression 
Matthew T. Wheeler, Keith A. Collins, Claudia E. Korcarz, Andrew A. Hack, Sara 
Zarnegar, Matthew Lyons, Elizabeth M. McNally, University of Chicago, Chicago, IL 
Background: In humans and mice, sarcoglycan gene mutations cause cardiomyopathy 
and muscular dystrophy characterized by focal cardiac necrosis, cardiomyopathy and 
vasospasm. Mice engineered to lack y-sarcoglycan show evidence of cardiomyopathy, 
but the contribution of vasospasm to this pathology is unknown. 
Methods: Smooth muscle tissues of ysarcoglycan mutant mice were studied by immun- 
ofluorascence and immunoblotting. Microvascular filling was used to evaluate vasos- 
pasm. ysarcoglycan mutant mice (n=lO) were treated with oral verapamil at 1 mg/kgiday 
for 5 months. Treated and untreated ysarcoglycan mutant mice were compared by tran- 
sthoracic echocardiography, ambulatory telemetry. histopathotogy, and microvascular 
filling analysis. 
Results: Microvascular filling of psarcoglycan mutant mice showed focal stenoses con- 
sistent with vasospasm. yet the sarcoglycan complex was not perturbed in vascular 
smooth muscle in ysarcoglycan mutant mice. These data indicate that vasospasm 
develops as a secondary consequence of intrinsic cardiomyocyte degeneration. Vera- 
pamil treatment to reduce secondary vasospasm in ysarcoglycan mutant mice attenu- 
ated mywardial fibrosis. Membrane permeability defects were present but reduced in 
verapamil-treated hearts. Verapamil-treated y-sarcoglycan mice had improved lefl ven- 
tricular fractional shortening (44.3% treated vs. 37.4% untreated), improved maximal 
velocity at the aortic outflow tract (114.9 vs. 92.6 cm/s. ~~0.05) and improved cardiac 
index (1.06 vs. 0.67 mllminig, p<O.OOl) compared to untreated mice. 
Conclusions: These data indicate that secondary, not primary, vasospasm contributes 
to cardiomyopathy progression in sarcoglycan gene mutations. Moreover, verapamil can 
reduce secondary vasospasm and limit the progression of cardiomyopathy. 
4:45 p.m. 
864-4 External Pharmacological Control of Vector-Based 
Phospholamban-Antisense-RNA Expression for the 
Flexible Modulation of Cardiac Calcium Homeostasis 
Wolfaana C. Poller, Henry Fechner, Xiaomin Wang, Dick Dekkers, Jos Lamer% 
University Hospital Benjamin Franklin, Berlin, Germany, Erasmus Universiteit Rotterdam, 
Rotterdam, The Netherlands 
Background: Impaired sarcoplasmic reticulum Ca2+ pump (SERCAP) activrty plays an 
important role in the development of diastolic dysfunction of the failing heart. Genetic 
complementation experiments in MLP-I- x PL-/- knock out mice, and other data, suggest 
that the expression ratlo of PL to SERCAP may be a target for the improvement of dias- 
tolic dysfunction in the failing heart. Previously we have developed PL-antisense-RNA 
strategies using either a consfitutive CMV or an endothelin-l-inducible ANF promoter. 
External control of applied vectors in viva can not be achieved using these systems. We 
report here on the application of a tetracycline (Tat)-inducible promotor to create vectors 
allowing “exogenous activation” by a drug. Methods and Results: In order to reduce 
background activation of the transgenes. PL-antisense-RNA (Plas) and PL-sense-mRNA 
(PLs) used as control, respectively, were cloned downstream of a Tetracyclin Response 
Element (TRE) in a first vector (AdSTRE-PLas). A second vector (Ads-rtTA) expresses a 
reverse tetracyclin Transactivator (rtTA). Analogous two-vector systems were developed 
for luciferase (Luc). The Tat-systems were compared to standard CMV vectors in neona- 
tal rat cardiomyocytes (CMCs). PL in CMCs, CaZ+ uptake activity in CMC homogenates, 
and Ca2+ transients in intact CM&, were measured using standard methods, Luc activ- 
ity by luminometry. More than 65 % of CMCs were routinely expressing both TRE-trans- 
gene and rtTA vector. In the TRE-Luc system, basal transgene activity in the absence of 
Tet was not significantly above the background, whereas at 4OQ nglml Tet, Luc activity 
was 46 % above that of the CMV vector. Under maximal stimulation, the TRE-PLas vec- 
tor had simtlar effects as the CMV-Plas vector upon dose-and time-dependent reduction 
of PL-mRNA and protein, Ca2+ uptake activity, and Ca2+ transients. Both TRE-PLs vec- 
tor and TRE-Plas without Tet had no significant effects. Conclusions: Pharmacological 
control of vector-based PL-antisense-RNA expression may become a more flexible gene 
therapy approach to the improvement of diastolic dysfunction than the previously used 
CMV and ANF promotor vectors, allowing rapid adaptation to the hemodynamic situation. 
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674-l Relation Between Changes in Ejection Fraction Over 
Time and Subsequent Mortality and Morbidity in Val- 
HeFf 
lnderiit S. Anand, Maylene Wang. Riberto Latini, Lloyd Fisher, Yann Tong Chiang, Jay N. 
Cohn, on behalf of the Val-HeFT Investigators, VA Medical Center and University of 
Minnesota, Minneapolis, MN, lstituto di Ricerche Farmacologiche “Mario Negri”, Mitano. 
Italy 
Background: Left ventricular remodeling is considered an important determinant of pro- 
gression of heart failure (HF), and ejection fraction (EF) has consistently been shown to 
predict mortality and morbidity (M&M). Whether changes in EF over time correspond to 
subsequent changes in M&M has not been studied. Such a relationship would further 
strengthen the role of LV remodeling as a surrogate for events. Val-HeFT evaluated the 
efficacy of the ARB valsartan in patients with moderate and severe HF and measured EF 
in over 5000 patients at baseline and over 4500 patients during follow-up, and provided 
data for this study. Methods: Change in echocardiographically derived EF from baseline 
(BL) to 4, 12, and 24 months were analyzed in subgroups by quartiles for subsequent 
M&M. Risk ratio (RR) and 95% Cl were calculated for M&M in all patrents, irrespective of 
treatment using Cox regression, adjusting for baseline EF. Results: BL EF in quartrles 
showed a significant quartile-dependent increase in M&M risk (data not shown). 
Changes in EF from BL to 4 months also showed a signrficant and corresponding change 
in M&M. As compared with patients who had no or little change in EF over time (quartile 
2) patients whose EF decreased (quartile 1) showed a srgnificant increase in RR for 
M&M, whereas patients with an increase in EF (quartiles 3 & 4) showed a decrease in 
RR for M&M. Similar findings were seen for changes in EF at 12 and 24 months. Conclu- 
sions: These data further reinforce the role of EF as a significant surrogate marker in HF. 
6:45 a.m. 
874-2 Hemodynamic Mechanisms of Ejection Fraction 
Improvement With Chronic Carvedilol Treatment in 
Heart Failure: Insights From Three-Dimensional 
Echocardiography 
Mathew S. Maurer, Daniel Burkhoff, Lyna El-Khoury Coffin, Donald L. King, Norma 
Medina. Madeline Yushak. Jonathan D. Sackner-Bernstein. Columbia Universitv. New 
York, NY, St. Luke’sRoosevelt Hospital, New York, NY 
Background. CarvedrIo is known to improve ejection fraction in patients wth CHF but the 
relative contributions of heart rate reduction, afterload reduction and positive inotropism 
to this beneficial effect are unknown. 
Methods. 32 patients (64+12 years old, 20 wth idiopathic and 12 with ischemic cardi- 
omyopathy) with NYHA II-111 underwent serial three dimensional echocardiogram (3DE) 
at baseline and 4 months after initiation of carvedilol. 3DE derived measures of LV vol- 
umes and mass were coupled with sphygmomanometic measurements of arterial pres- 
sures yielding estimates of chamber contractility (end-systolic pressure-volume ratio, 
Res, where PesSBP’O.S), effective arterial elastance (Ea, -TPR’GO/HR) and ventricular 
vascular coupling (EefRes). 
Results. EF increased by 6 f 6 percentage points (from 26+6% to 32*9%, p<O.OOOl). 
The change in EF was correlated with changes in stroke volume (w0.66. p<O.OOOl) but 
not wth changes in end diastolic volume (r=.09, p=NS). Pressure-volume based analysis 
show that Res increased from 0.72*0.39 to 0.60+0.36 mmHg/ml (p=O.O3). Ea decreased 
from 2.liO.6 to 1.7kO.5 mmHg/ml (pcO.001). which was due to a significant decrease in 
HR (from 63+11 to 65+6 bpm, p<O.OOl) with no significant change in TPR (1.3kO.4 vs 
1.3iO.4 ml/mmHglmin). Ea/Res improved from 3.4&1.5 to 2.5il.3 (pcO.001). 
Conclusions: Improved chamber contractility (indexed by increased Res) and decreased 
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HR each contributed significantly to the improvement in EF observed with chronic O- 
blocker treatment. Reverse remodeling (i.e., decreased end-diastolic volume) is not a 
major factor. 
Adjusted Estimates of Percentage Surviving 
9:oo a.m. 
874-3 Predictors of Mortality in Patients With Heart Failure 
and Preserved Systolic Function in the Digitalis 
Investigation Group Trial 
Patient Groups 
EF<35,SRS<15 
EF 535, SRS > 15 
EF z-35, SRS < 15 
EF >35, SRS > 15 
1 Yr 3 Yr 5 Y’ 
94.3 83.3 71.9 
93.7 77.1 58.1 
98.5 89.7 81.3 
98.3 85.8 80.0 
R. Christopher Jones, Eugene H. Blackstone. Gary S. Francis, Michael S. Lauer, The 
Cleveland Clinic Foundation, Cleveland, OH 
9:30 a.m. 
Background: Although diastolic heart failure is common, the factors that predict mortal- 
sty have not been clearly defined. 
Methods: We studied 988 patients (59% men) with documented heart failure and ejec- 
tion fraction > 45% who were enrolled and prospectively followed in the Digitalis Investi- 
gation Group (DIG) trial. During 3.1 years of follow-up, there were 231 deaths (23%). 
Results: The average age was 87210 years, and the average ejection fraction was 
Ss+_S%. There were 285 patients with diabetes (29%) and 557 with fschemlc head dis- 
ease (57%). In univariable analyses, predictors of death included older age, increasing 
serum creatinine, decreasing body mass index, and presence of diabetes (Figure shows 
quartiles or presence of these versus 3-year Kaplan-M&r death rates). 
874-5 Improvement in Global and Segmental Left Ventricular 
Contractility Following Autologous Bone Marrow Cell 
Transplantation in Humans With Severe lschemic Heart 
Failure 
Emerson C. Penn, Hans F. Dohmann, Radovan Borojevic, Hans J. Dohmann, Antonio C. 
Carvalho, Yong J. Geng, Andre Luiz S. Sousa, Guilherme V. Silva, Fernando Rangel, 
Swarm A. Silva, Isabel Rossi, Roberto Esporcatte, James T. WilIerson, Texas Head 
Institute, Houston, TX, Hospital Pro-Cardiaco, Rio de Janew Brazil 
Backgrounci Limited treatment options exist for pts with end-stage ischemic heart fail- 
ure (HF) notamenable to revascularization. We evaluated the effect of transendwardial 
(TE) delivery of autologous bone marrow mononuclear cells (BMNC) in pts with severe 
HF. 
Gender, ejection fraction, and etiology of heart failure were not predictors of death. In 
stepwise multivariable Cox regression analyses that considered 20 covariates. indepen- 
dent predictors of death were increasing creatinine (score 2 = 88, P < O.OOOl), NYHA 
class (f = 25, P < 0.0001). recent worsening heart failure (x2 = 12, P = 0.0005), older 
age (x2 = 10, P = 0.0017), body mass index (x2 = 4, P = 0.038), diabetes (x2 = 5. P = 
0.023). and use of diuretics (x2 = 4, P = 0.038). 
Conclusions: Diastolic heart failure is associated with a high death rate. Important pre- 
dictors of death include age, renal function, functional class, body mass index, and dia- 
betes. 
9:15 a.m. 
874-4 Assessment of Long-Term Outcome in a Population at 
High Risk for Coronary Artery Disease: Mortality Risk 
Associated With Ejection Fraction Differs Across 
Resting Nuclear Perfusion Findings 
Jam&on M. Bouraue. Linda K. Shaw, Eric J. Velazquez, Christopher M. O’Connor, 
Salvador Barges-Neto, Duke University Medical Center, Durham, NC 
Background: Resting myocardial perfusion studies assess myocardial viability in 
patients with heart failure. The sum rest score (SRS), a marker for perfusion abnormality 
severity at rest, provides independent prognostic information for patients at low to inter- 
mediate risk for coronary artery disease (CAD). However, its prognostic role and poten- 
tial interaction with ejection fraction (EF) in a high risk population are less well defined. 
Methods: We examined 3,275 patients at high risk for CAD who underwent cardiac cath- 
eterization and nuclear imaging within a six month interval and were followed up to 8 
years. We used Cox proportional hazards modeling to assess the relationship between 
EF and SRS after adjusting for significant clinical characteristics. 
Results: A significant interaction (p=O.O30) was found between the nuclear SRS and EF. 
Each 10% decrease in EF for patients with a low risk SRS of 1 provided a 29% increase 
m mortality risk (p=O.OOl, hazard ratio (HR) =1.29. 95% confidence interval (Cl) 1.19- 
1.40). while those wth a hfgh risk SRS of 8 (cohort 75” percentile) had a 37% increase 
(p=O.OOl, HR 1.37, 95% Cl 1.23-l .52). Adjusted survival estimates across SRS levels 
and EF groups were obsewed (see table). 
Conclusion: Resting perfusion studies significantly Impact the interpretation of mortality 
risk associated with changes in resting EF. This clinical interaction should be taken into 
account when nuclear perfusion imagmg is performed to assess prognosis and viability in 
the low EF populabon. 
Methods Ten pts (58 f 11 yrs, 7 males) with severe LV dysfunction (EF 19 + 10 %) and 
were included. Bone marrow (50ml) was aspirated and BMNCs were isolated. TE injec- 
tions were performed using the Myo-Star catheter (NOGA, Biosense) to target hibemat- 
ing myocardium guided by electromechanical mapping (EMM). Pts were evaluated by 
a)angiography (LVEF) b) EMM (mean values of linear local shortening (LLS) and unlpo- 
lar voltage (UniV)) and c)echo (wall motion score index). LVEF and treated vs. non- 
treated segments were analyzed before and 18 wks after the procedure. Student’s paired 
T-test was utilized. 
Resultr On angiography LVEF increased from 19*9% to 24~12% (p=O.O05). A total of 
18 myocardial segments were injected (2kO.7 per pt). On EMM the mean LLS values in 
the treated areas increased from 5.7*3.7% to 10.8*3.5 % (p=O.O05) UniV values of the 
treated segments did not vary significantly after cell therapy (from 10.5 r 3.5 to 10.3 * 2.7 
mV; p=O.8). 
By echocardiography the wall motion score index decreased from 2.0 * 0.7 to 1.8 * 0.8 
(p=O.OOOS) in the treated segments and from 1.9*0.3 to 1.7r0.2 (p=O.Ol) in the non- 
treated segments. 
Conclusion In this small number of pts there was an overall lmprovent in LVEF by 
angiography following TE injection of BMNC at 18wk follow-up. There was improvement 
in segmental contractility in the treated areas by both echocardiographic and EMM crite- 
ria. Future studies are needed to further clarify the role of stem-cell therapy m the treat- 
ment of severe HF. 
9:45 a.m. 
874-6 The Association of Left Ventricular Ejection Fraction, 
Mortality, and Cause of Death in Stable Patients With 
Heart Failure 
Jeptha P. Cur&., Seth I. Sokol. Yongfei Wang, Saif S. Rathote, Dennis T. Ko, Farid 
Jadbabaie, Edward L. Portnay, Stephen J. Marshalko, Martha J. Radford, Harlan M. 
Krumholz, Yale University School of Medicine, New Haven, CT 
Background Left ventricular ejection fraction (LVEF) IS used as a predictor of prognosis 
in heart failure (HF) patients. but the manner in which the associatton of LVEF, mortality, 
and cause of death vanes across the full spectrum of LVEF is incompletely understood. 
Methods and Results: We examined the association of LVEF and outcomes in 7788 
patients enrolled in the Digitalis Investigation Group trial. With mean follow-up of 37 
months, mortality was substantial in all LVEF groups (range LVER15%: 51.7%, >55: 
23.5%). Among pabents with LVEK45%. mortality rates decreased in a near linear fash- 
ion across successively higher LVEF groups (LVEM15%: 51.7%; LVEF 38-45%. 25.8%; 
PcO.OOl), but mortality was comparable in LVEF groups above 45% (LVEF 48.55%: 
23.3%, LVEF>55%: 23.5%; P=O.25). In multivariable analysis, the magnitude of the 
association was reduced (LVERlS%: HR 1.84. Cl 1.54-2.18; 18-25%: HR 1.47, Cl 1.30. 
1.85; 28.35%: HR 1.13, Cl 1.01.1’.28; 38-45%: referent; 48-55%: HR 0.91, Cl 0.78-1.09; 
~-55%: HR 0.89, Cl 0.71-l .lO). Patients with lower LVEF were at increased risk of death 
due to arrhythmia and worsening HF, but these wars leading causes of death in all LVEF 
groups. 
Conclusions Annual mortality was more than 5.5% in all LVEF groups, but lower LVEF 
